依沙佐米治疗难治性/复发性多发性骨髓瘤临床试验效果的Meta分析

目的:评价依沙佐米治疗难治性/复发性多发性骨髓瘤(RRMM)的疗效及安全性。方法:计算机检索依沙佐米治疗RRMM的临床试验,手工检索纳入查询到的所有文献,提取数据后,使用R软件3.5.0进行Meta分析。结果:共纳入8篇文献,包括1096例RRMM患者,含依沙佐米三联方案的疗效优于单联方案或双联方案,以依沙佐米联合来那度胺和地塞米松(IRD)方案疗效最佳;IRD方案腹泻,恶心,皮疹,血小板减少,呕吐,腹泻≥3级,低血压≥3级,恶心≥3级高于来那度胺和地塞米松(RD)方案,而失眠,贫血≥3级低于RD方案,差异有统计学意义(P<0.05)。结论:含依沙佐米三联方案治疗RRMM的疗效较依沙佐米单联方案或二联方案显著。IRD方案疗效最佳,其不良反应较RD方案增多。

The Meta-analysis on the Clinical Trial Results of a Patient/Recurrent Multiple Myeloma in Ixazomib

Objective:To evaluate the efficacy and safety of Ixazomib in the treatment of refractory/relapsed multiple myeloma(RRMM).Methods:The clinical trials of Ixazomib in the treatment of RRMM were searched by computer,and all the literature included in the inquiry and relevant references were manually searched.And after extracting the data,using the R software 3.5.0 for Meta-analysis.Results:A total of 8 articles were included,including 1096 patients with RRMM.The efficacy of the triple regimen with Ixazomib was better than that of the single regimen or the double regimens.The efficacy of lenalidomide and dexamethasone combined with Ixazomib(IRD)was best;The IRD regimen had diarrhea,nausea,rash,thrombocytopenia,vomiting,Diarrhea in adverse events≥3 grade,hypotensionin adverse events≥3grade,nausea in adverse events≥3 grade higher than RD regimen,and insomnia,anemiain adverse events≥3 grade was lower than lenalidomide and dexamethasone(RD)regimen,the difference was statistically significant(P<0.05).Conclusions:The efficacy of the triple regimen with Ixazomib in the treatment of RRMM is significantly greater than that of the Ixazomib singly regimen or two regimens,IRD regimen has the best therapeutic effect,while the adverse effects of the IRD regimen are greater than those of the RD regimen.